The following article originally appeared in Pharmaceutical Executive Magazine's January 2021 issue.
Other content in this Stream
In this issue of Clinical Watch, we discuss new antipsychotic medication formulations to tailor the management of schizophrenia and suggest prior authorization criteria for a new treatment for Cushing
Advanced digital capabilities take the stress out of the busiest time of the year
In this issue of Clinical Watch, we discuss nitrosamine impurities found in widely used medications and suggest prior authorization criteria for a new treatment for heavy menstrual bleeding
In this issue of Clinical Watch, we highlight the use of diabetes drugs in the treatment of heart failure and suggest prior authorization criteria for the first approved treatment of plexiform neurofi
Public health professionals have been sounding the alarm for years, but the COVID-19 pandemic and the sweeping protests following the death of George Floyd have brought the message front and center